GRAIL Stock for Accredited Investors

Biotech / Life Sciences
By UpMarket Research  |  Last updated: July 2026
Founded 2016 HQ Menlo Park, US

GRAIL is a healthcare company focused on early cancer detection using next-generation sequencing, clinical studies, machine learning, software, and automation. It develops blood-based tests intended to identify cancers before symptoms appear, aiming to improve treatment outcomes.

Access to pre-IPO shares is available to accredited investors through UpMarket.

Latest Price
Previous Price
Series D Apr 2020

How to Invest in GRAIL Through UpMarket

GRAIL shares are not on public exchanges. UpMarket provides accredited investors access through secondary market transactions.

Step 01

Verify accredited investor status

Confirm eligibility under SEC Rule 501 of Regulation D. Income or net worth threshold applies.

Step 02

Create an UpMarket account

Complete KYC/AML onboarding. Typically 1–2 business days. Licensed rep assigned on signup.

Step 03

Review available GRAIL offerings

Full offering memoranda and risk disclosures provided before any commitment is required.

Step 04

Complete subscription documents

Review and sign subscription agreement. All documents handled digitally through the platform.

Step 05

Fund your investment

Wire transfer or ACH. $50K minimum. Funds held in custodial account until close.

Pre-IPO investments are illiquid, speculative, and involve risk of total loss of capital.

$1.3B+
UpMarket has brokered over $1.3 billion in alternative investments*
*Includes principal invested and appreciation of investments originated via the UpMarket platform based on historical trade volume and valuation estimates through March 31, 2026. Of the total, approximately $301 million is managed by UpMarket Management, with the remaining originated investments managed by affiliates. Past performance is not predictive of future results.

Valuation Growth Over Time

Post-money valuation by round
Previous rounds Most recent
DateRoundPPS (split-adj.)Valuation
Jun 2020 Series D
Apr 2020 Series D
Mar 2018 Series C
May 2017 Series B
Jan 2016 Series A

GRAIL Revenue and Growth

Annual revenue

Why Investors Are Watching GRAIL

Growth Signal

GRAIL raises $325M to extend runway and fund growth

GRAIL announced a $325.0 million private placement with new and existing institutional investors, including Deep Track Capital and Farallon Capital. The company said its cash, cash equivalents and investments, including net proceeds, are expected to provide sufficient funding for its plans.

Product Milestone

GRAIL builds blood tests for earliest-stage cancer detection

Dealroom describes GRAIL as developing blood tests for early cancer detection using high-intensity sequencing, population-scale clinical trials, and computer science and data science. The company’s core product focus is identifying cancer at its earliest stages to improve treatment outcomes.

Market Opportunity

Multi-cancer screening targets a large unmet oncology market

GRAIL’s approach targets early cancer detection across multiple cancer types, a market framed around improving outcomes by finding disease before symptoms appear. The company’s recent financing suggests investor belief in continued demand for large-scale screening and diagnostics.

Interested in GRAIL stock? Fill out the form above or sign up directly. Subject to availability. Accredited investors only.

Request access →

GRAIL Leadership Team

Bob Ragusa
CEO
Joshua Ofman
President
Sir Harpal Kumar
President

UpMarket Investment Curation Process

  • Full diligence on every offering

    UpMarket curates and conducts independent diligence on every investment opportunity before it reaches the platform.

  • Strategy, fees & legal reviewed in full

    We review every offering's strategy, risk management, liquidity, fees, valuation methodology, tax matters, and all third-party providers — legal counsel, auditor, administrator, and custodian.

  • Disciplined managers only

    We offer investments exclusively from disciplined managers that pursue unique strategies across an array of asset classes.

  • Built around your objectives

    Our goal is to empower you to build a portfolio that best meets your individual investment objectives.

Ready to access institutional-grade private market investments? Unlock private markets

GRAIL Stock FAQ

No. As of March 2026, GRAIL is a private company and does not trade on any public stock exchange. Accredited investors can access GRAIL shares through UpMarket, a FINRA-registered broker-dealer that specializes in pre-IPO investments.

GRAIL does not have a public stock price because it is privately held. The most recent known share price comes from its last funding round. Pre-IPO share prices on the secondary market may differ from the last round price depending on supply, demand, and market conditions.

Yes. Accredited investors can indicate interest in GRAIL shares through UpMarket by filling out the form on this page or creating an account at upmarket.co. All pre-IPO offerings are subject to availability and require a $50,000 minimum investment. UpMarket is a FINRA-registered broker-dealer and has brokered more than $500M in alternative investments since 2019.

Pre-IPO investments carry significant risks. GRAIL shares are illiquid, meaning there is no public market to sell them quickly. There is no guaranteed exit timeline or return. The investment is speculative in nature, and investors should be prepared for the possibility of total loss. Valuations of private companies can fluctuate substantially between funding rounds. Investors should consult their financial advisor and review all offering documents before investing.

In a pre-IPO transaction, accredited investors purchase shares from existing shareholders (such as employees, early investors, or other holders) through secondary market platforms. The company itself does not issue new shares in these transactions. UpMarket facilitates these trades as a FINRA-registered broker-dealer, handling compliance, documentation, and settlement on behalf of both parties.

There are two primary exit paths for pre-IPO holdings: selling your shares on the secondary market to another buyer, or holding until the company completes an IPO or is acquired. Both paths are subject to transfer restrictions, company approval (right of first refusal), and market conditions. The timing of any exit is unpredictable, and investors should plan for a multi-year holding period.

The minimum investment for most pre-IPO offerings on UpMarket is $50,000. This amount may vary depending on the specific offering and share availability. There are no fees to create an UpMarket account or browse available investments. Investors only pay transaction-related fees when they complete an investment.

UpMarket's valuation estimate of is derived from a proprietary model that incorporates multiple data sources: funding round data (Caplight), revenue estimates (Sacra), secondary market pricing, and public company comparables. The model applies a private company discount to the public comp multiple to account for illiquidity and information asymmetry. This estimate is not investment advice and may differ substantially from the price at which shares actually trade.

GRAIL generated $147.2M in 2025 revenue and focuses on early cancer detection through next-generation sequencing, clinical studies, machine learning, software, and automation, while its $325M capital raise extends runway and funds growth — accredited investors can access GRAIL stock through UpMarket.

Invest in GRAIL Request access